NovoCure Limited · NASDAQ:NVCR
NovoCure — Investor Presentation (January 2024)
34 slides from NovoCure's investor presentation, January 2024
Slide 1: © s oO & = = AW = ise) ror
© s 2 oO & = = AW = ise) ror
Slide 2: Forward-looking statements
novocure forward-looking statements In addition to historical facts or statements of current condition, this presentation may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding a
Slide 3: 2023 achievements and 2024 milestones ahead
2025 achievements and 2024 milestones ahead DRIVING COMMERCIAL ADVANCING ADOPTION CLINICAL TRIALS 2023 France reimbursement LUNAR data presented New array launched ACHIEVEMENTS — achieved and launch LUNAR U.S. FDA PMA, CE Mark in Europe and Japanese PMDA submitted New array FDA PMA METIS enrollment
Slide 4: Together with our patients, we strive to extend survival
together with our patients, we strive to extend survival in some of the most aggressive forms of cancer patientforward”
Slide 5: Tumor Treating Fields are selectively tuned electric fields
novocure’ Tumor Treating Fields (TTFields) are selectively tuned electric fields that exert physical forces to kill cancer cells TUNED ELECTRIC FIELDS DISRUPT PROTEINS DURING CELL DIVISION CAUSING CANCER CELL DEATH TTFields 100 to 500 kHz tumor cell healthy cell patientforward® © 2024Novocure GmbH 5
Slide 6: Optune wearable cancer therapy system
novecure’ Optune® wearable cancer therapy system DELIVERS CONTINUOUS TUMOR TREATING FIELDS THERAPY TO SOLID TUMORS TWO PRIMARY COMPONENTS electric field generator and transducer arrays TTT ae patientforward” Optune tended as @ treatment for adult patients (22 years of Folder) with histologically-con
Slide 7: Strategy for long-term growth
novecure’ Strategy for long-term growth drive commercial advance deliver adoption clinical trials product innovation in approved to reach new patient to increase dose and indications populations duration of therapy patientforward” © 2024 Novocure GmbH 7
Slide 8: Three focused objectives in 2024
three focused objectives in 2024 JY{OPTUNE cio” LAUNCH LUNG DELIVER PIPELINE \ SESa ss forward’ GEM, alioblastoma
Slide 9: Optune Gio: established in glioblastoma
Slide 10: Optune Gio proven to extend patient survival
novecure’ Optune Gio proven to extend patient survival EF-14 PHASE 3 PIVOTAL STUDY IN NEWLY DIAGNOSED GBM Overall survival (5-year survival analysis) oT Boon TN A rons | 202 | 360 NEARLY HALF 0.9 7) Log-rank P-value <0.001 43 % Si pespia win 08 4 HR (95% Cl) 0.63 (0.53-0.76) (0) . ig 07 exec Hedian
Slide 11: Optune Gio: greater exposure increased survival
novecure’ Optune Gio: greater exposure increased survival 25 months p<0.05 22 months p<0.05 20 months P<0.05 OF PATIENTS RECEIVED A SURVIVAL ' econ BENEFIT FROM OPTUNE GIO BECAUSE "46 months THEY USED IT >50% OF THE TIME 10 20 30 Median Overall Survival, months ANNUAL SURVIVAL RATE OF HIGHEST USAGE
Slide 12: Real-world evidence demonstrates long and durable survival benefit
novecure’ real-world evidence demonstrates long and durable survival Probability of Survival patientforward: benefit with Optune Gio nl ee OVERALL SURVIVAL FOR U.S. PATIENTS FROM OPTUNE GIO START (N=974) 4 1% e) POST-PROGRESSION SURVIVAL FOR PATIENTS CONTINUING OPTUNE GIO (N=59}! no toxicity INCREAS
Slide 13: LUNAR trial met primary endpoint
novecure’ phase 5 LUNAR trial met primary endpoint STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN OS 10 Median OS (months) 13.2 | 99 13.2 months o9 4 Log-rank P-value 0.035, . . HR (95% Cl) 0.74 (0.56-0.98) mOS with TTFields + SOC 08 4 3-year survival (95% Cl) 18% (11-27) ] 7% (2
Slide 14: Significant opportunity to treat NSCLC patients
Significant opportunity to treat NSCLC patients 114K stage IV NSCLC 1L patients in the U.S. ~3 0,000 >7 YEARS since any therapy 60% has shown a significant improvement in overall survival in 50% 2L NSCLC receive 1L platinum-based chemotherapy progress and seek 2L treatment forward © 2024Novocure Gmb
Slide 15: Preparing for 2024 NSCLC launch
novecure’ preparing for 2024 NSCLC launch 0 2023 O 2024 2025 L_ COMMERCIAL LAUNCH REGULATORY PATHWAY v HCP and patient campaigns . ¥ DTC campaign ¥ CE mark submitted CLINICAL DATA v F V PMA submitted to U.S. FDA Global advisory boards v Announced top-line results v¥ KOL engagements v Japanese PMDA s
Slide 16: Phase 3 top-line data in 2024
novecure’ phase 3 top-line data in 2024 PANOVA-3 Pancreatic Cancer TTFields + gemcitabine, nab-paclitaxel in 1L pancreatic cancer TOP-LINE DATA ANTICIPATED Q4 2024 © 2024Novocure GmbH 16
Slide 17: Ongoing Phase 2 and 3 trials
PHASE 3 PHASE 2 METIS KEYNOTE-B36 TTFields monotherapy treating brai TTFields + pembrolizumab treating 1L metastases from NSC or metastatic NSCLC LUNAR-2 LUNAR-4 TTFields + pembrolizumab + chemotherapy TTFields + ICI treating 2L metastatic NSCLC treating 1L metastatic NSCLC following prior ICI treat
Slide 18: Prioritizing growth and path to profitability
prioritizing growth and path to profitability OPTIMIZED OPERATIONS Funding future without increased cash burn ACCELERATE PATH TO PROFITABILITY forward © 2024NovocureGmbH 18
Slide 19: Significant pipeline catalysts on foundation of positive cashflow business
novecure’ Significant pipeline catalysts on foundation of positive cashflow business METIS data LUNG APPROVALS & LAUNCH PANOVA-3 data PROFITABLE GBM BUSINESS patientforward® = : © 2024 Novocure GmbH 19
Slide 20: Appendix
novecure’ appendix patientforward”
Slide 21: Therapy is frequency-tuned to target dividing cancer cells
novecure’ therapy is frequency-tuned to target dividing cancer cells }H————__— TUMOR TREATING FIELDS 150 kHz 100 kHz 150 kHz 200 kHz 10 kHz 250 kHz Low Frequencies Intermediate High Frequencies DNA Damage cardiac defibrillator Frequencies radiofrequency ablation ionizing pacemaker Tumor Treating rad
Slide 22: TTFields have multiple, distinct mechanisms of action
novecure’ TTFields have multiple, distinct mechanisms of action interference of cell movement and migration disruption of mitosis “ a mechanisms work ° together to selectively target and disrupt the progression of cancer cells, which can lead downregulation of . to their death downstream enhancement
Slide 23: Product roadmap to prioritize dose and efficacy
product roadmap to prioritize dose and efficacy field generator arrays software applications next gen device new arrays MAXPOINT™ in development treating patients through planning software limited market release in development forward” © 2024Novocure GmbH 23
Slide 24: Optimized dose delivered can lead to increased efficacy
novecure’ optimized dose delivered can lead to increased efficacy TUMOR TREATING FIELDS DOSE Wins stato DELIVERED TO TUMOR OF TISSUE —a TIME ON xX FIELD INTENSITY xX CONDUCTIVITY om, patientfo rward™ © 2024 Novocure GmbH 24 Ballo MT, et a. Correlation of Tumor Treating Fields Dosimetry to Survival O
Slide 25: New lighter, thinner arrays deliver greater intensity
novecure’ new lighter, thinner arrays deliver greater intensity an EXISTING ARRAYS NEW ARRAYS AP channel, 1,364 mAmps AP channel, 1,685 mAmps 0 V/cm PMA SUPPLEMENT SUBMITTED IN @4 2023 patientforwa rd” © 2024Novocure GmbH 25 obtained from pa
Slide 26: Ongoing trial designs
novecure’ ongoing trial designs © patientforward™ © 2024Novocure GmbH 26
Slide 27: METIS: Phase 3 trial in brain metastases from NSCLC
novecure’ METIS: phase 3 trial in brain metastases from non- small cell lung cancer OPEN-LABEL, RANDOMIZED TRIAL DESIGN* stereotactic Se Tumor Treating Fields — MRI q2m until radiosurgery progression screening and baseline ii evaluation stereotactic MRI i ‘EEE EE _ STUDY DESIGN * 270 patients with 1
Slide 28: PANOVA-3: Phase 3 trial in locally advanced pancreatic cancer
novecure’ PANOVA-3: phase 3 trial in locally advanced pancreatic cancer OPEN-LABEL, RANDOMIZED TRIAL DESIGN* screening and EZ baseline evaluation STUDY DESIGN 556 patients with 18-month minimum follow-up Primary endpoint: overall survival TTFields + nab-paclitaxel + gemcitabine post-PD follow up vis
Slide 29: PANOVA-4: Phase 2 trial in metastatic pancreatic cancer
novecure’ PANOVA-4: phase 2 trial in metastatic pancreatic cancer PILOT, SINGLE-ARM TRIAL DESIGN! TTFields + screening and baseline J = atezolizumab+ [im CT q8w until | - post-PD _ survival evaluation nab-paclitaxel + progression follow up visit follow-up q3m gemcitabine STUDY DESIGN + 76 patients w
Slide 30: TRIDENT: Phase 3 trial in newly diagnosed glioblastoma
TRIDENT: phase $ trial in newly diagnosed glioblastoma OPEN-LABEL, RANDOMIZED TRIAL DESIGN* TTFields + radiation TTFields + therapy + TMZ maintenance TMZ screening and baseline evaluation Radiation therapy TTFields + +TMZ maintenance TMZ = = 9 ro a = re} nol = fw STUDY DESIGN 950 patients with 24-mo
Slide 31: LUNAR-2: Phase 3 trial in metastatic NSCLC
novecure’ LUNAR-2: phase 3 trial in metastatic non-small cell lung cancer OPEN-LABEL RANDOMIZED TRIAL DESIGN TTFields + pembrolizumab + CT/follow-up q3w survival until progression follow-up platinum-based chemotherapy screening and baseline evaluation pembrolizumab + platinum-based CT/follow-up q3w
Slide 32: KEYNOTE B36: Phase 2 trial in NSCLC
novecure’ KEYNOTE B36: phase 2 trial in locally advanced or metastatic non-small cell lung cancer OPEN-LABEL RANDOMIZED TRIAL DESIGN? =I a . follow-up q survival 5 Y TTFields + pembrolizumab a qow follow-up screening and baseline = evaluation PS N & \ r follow-up q3w, survival £ pembrolizumab = gow
Slide 33: Optune Lua and Optune Gio indications for use and important safety information
novecure’ Optune Lua® and Optune Gio™ indications for use and important safety information INDICATIONS * Optune Gio is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM). * Optune Gio with temozolomide is indicated for th
Slide 34: Optune Lua and Optune Gio indications for use and important safety information
novecure’ Optune Lua® and Optune Gio™ indications for use and important safety information WARNINGS AND PRECAUTIONS * Optune Gio and Optune Lua can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure®. * The most common (210%) adver